Cargando…

The 2013 clinical course descriptors for multiple sclerosis: A clarification

The clinical courses of multiple sclerosis were defined in 1996 and refined in 2013 to provide a time-based assessment of the current status of the individual. These definitions have been successfully used by clinicians, clinical trialists, and regulatory authorities. Recent regulatory decisions pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lublin, Fred D., Coetzee, Timothy, Cohen, Jeffrey A., Marrie, Ruth A., Thompson, Alan J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Views & Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455332/ https://www.ncbi.nlm.nih.gov/pubmed/32471886 http://dx.doi.org/10.1212/WNL.0000000000009636

Ejemplares similares

Defining the clinical course of multiple sclerosis: The 2013 revisions
por: Lublin, Fred D., et al.
Publicado: (2014)

The challenge of comorbidity in clinical trials for multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2016)

Do the current MS clinical course descriptors need to change and if so how? A survey of the MS community
por: Thompson, Alan J, et al.
Publicado: (2023)

Recommendations for observational studies of comorbidity in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2016)

The topographical model of multiple sclerosis: A dynamic visualization of disease course
por: Krieger, Stephen C., et al.
Publicado: (2016)

Visibility and representation of women in multiple sclerosis research
por: Thomson, Alison, et al.
Publicado: (2019)

Relapsing experimental allergic encephalomyelitis an autoimmune model of multiple sclerosis
por: Lublin, Fred D.
Publicado: (1985)

Clinical course of multiple sclerosis and patient experiences during breast cancer treatment
por: Nylander, Alyssa N, et al.
Publicado: (2023)

Infectious causes of multiple sclerosis
por: Gilden, Donald H
Publicado: (2005)

Cognition in multiple sclerosis: State of the field and priorities for the future
por: Sumowski, James F., et al.
Publicado: (2018)

Nonconventional MRI biomarkers for in vivo monitoring of pathogenesis in multiple sclerosis
por: Londoño, Ana C., et al.
Publicado: (2014)

Differential involvement of amyloidogenic evolvability in oligodendropathies; Multiple Sclerosis and Multiple System Atrophy
por: Wei, Jianshe, et al.
Publicado: (2023)

Improving quality, affordability, and equity of multiple sclerosis care
por: Langer‐Gould, Annette, et al.
Publicado: (2021)

Can We Treat Secondary Progressive Multiple Sclerosis Now?
por: Bhatia, Rohit, et al.
Publicado: (2019)

Serum neurofilament light as a biomarker in progressive multiple sclerosis
por: Kapoor, Raju, et al.
Publicado: (2020)

Polygenicity of Comorbid Depression in Multiple Sclerosis
por: Kowalec, Kaarina, et al.
Publicado: (2023)

Association of Vitamin D Polygenic Risk Scores and Disease Outcome in People With Multiple Sclerosis
por: Vasileiou, Eleni S., et al.
Publicado: (2022)

Music-based therapy in rehabilitation of people with multiple sclerosis: a systematic review of clinical trials
por: Lopes, Josiane, et al.
Publicado: (2021)

Chronic cerebrospinal venous insufficiency in Multiple Sclerosis: A note for caution
por: Bhatia, Rohit, et al.
Publicado: (2012)

No Evidence of Disease Activity (NEDA) in Multiple Sclerosis - Shifting the Goal Posts
por: Pandit, Lekha
Publicado: (2019)

An argument for broad use of high efficacy treatments in early multiple sclerosis
por: Stankiewicz, James M., et al.
Publicado: (2019)

COVID-19 Among Patients With Multiple Sclerosis: A Systematic Review
por: Barzegar, Mahdi, et al.
Publicado: (2021)

News and Views–December 2013
Publicado: (2013)

The multiple sclerosis relapse experience: patient-reported outcomes from the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry
por: Nickerson, Molly, et al.
Publicado: (2013)

Pathways to cures for multiple sclerosis: A research roadmap
por: Bebo, Bruce F, et al.
Publicado: (2022)

Response of the multiple sclerosis community to COVID-19
por: Ciccarelli, Olga, et al.
Publicado: (2020)

The Barancik lecture: Comorbidity in multiple sclerosis—Looking backward, looking forward
por: Marrie, Ruth Ann
Publicado: (2023)

Emergency Medical Care of Multiple Sclerosis Patients: Primary Data from the Mount Sinai Resource Utilization in Multiple Sclerosis Project
por: Oynhausen, Svenja, et al.
Publicado: (2014)

Some clarifications regarding multiple comparisons
por: Frane, Andrew V.
Publicado: (2016)

Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment
por: Cohen, Jeffrey A, et al.
Publicado: (2019)

A systematic review of the incidence and prevalence of cancer in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

Balancing Potential Benefits and Risks of Bruton Tyrosine Kinase Inhibitor Therapies in Multiple Sclerosis During the COVID-19 Pandemic
por: Weber, Martin S., et al.
Publicado: (2021)

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
por: Polman, Chris H, et al.
Publicado: (2011)

The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

Clarification
Publicado: (2007)

Clarification
Publicado: (2009)

Clarification
Publicado: (2013)

World diabetes day 2013: diabetes mellitus and nephrology
por: Hajivandi, Abdolah, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ikqineghmkitephmc0491e7cf0